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1. Abstract  
Drugs of abuse, such as opioids and amphetamines, represents nowadays a serious global 
problem which has economical, psychological, social and medical impact. Investigation of 
drug effects on the nervous system has been a subject of many studies during the last few 
decades. The interest in neurons regarding this issues is rather constant, but currently there is 
increasing number of studies focused on neuroglia and their role in drug addiction. Many 
studies demonstrated that glia are not only a part of neuropile and do not have only supporting 
function, but they play an important role in communication between neurons, participate in 
modulation of neurotransmission and could produce factors such as cytokines and 
chemokines. However, there is a not much information about the effect of drugs of abuse on 
neuroglia and the presumed role of these cells in the development of addiction in not quite  
clear. This review aims to provide a brief survey of current knowledge on this topic. 
 





Drogy ako opioidy a amfetamíny predstavujú v súčastnosti celosvetový problém, ktorý má 
ekonomický, psychologický, sociálny a medicínsky dosah. Skúmanie účinkov drôg na 
nervový systém sa stal predmetom mnohých štúdií posledných desaťročí. Záujem o výskum 
neurónov v súvislosti s touto problematikou je konštantný, avšak v súčasnej dobe sa zvyšuje 
počet štúdií, ktoré sa zameriavajú na výskum neuroglií a ich úlohy pri drogových závislostí. 
Mnoho výskumov ukazuje, že že glie nie sú len súčasťou neuropilu a nemajú len podpornú 
funkciu, avšak hrajú významnú úlohu v komunikácii medzi neurónmi, podieľajú sa na 
modulácii nervového prenosu a dokážu produkovať pôsobky ako cytokíny a chemokíny. 
Avšak, nie je mnoho informácií o účinkoch drôg na neuroglie a ich predpokladaná úloha 
v rozvoji závislosti nie je úplne jasná. Táto štúdia má za cieľ poskytnúť stručný prehľad 
poznatkov o tejto téme.  
 






3. List of abbreviations 
ACM - astrocyte conditioned medium 
AMP - adenosine monophosphate 
AMPA - alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ATP - adenosine triphosphate 
ATS - amphetamine type stimulants 
BDNF - brain-derived neurotrophic factor 
bFGF - basic fibroblast growth factor 
cAMP - cyclic adenosine monophosphate 
CD - cluster of differentiation 
CeA - central nucleus of amygdala 
CCL - CC chemokine ligand 
CNS - central nervous system 
CREB - cAMP-element binding protein 
EAAT - excitatory amino acid transporters 
Fos - FBJ murine osteosarcoma viral oncogene homolog 
fra-  FOS-like antigen 
GABA - gamma-aminobutyric acid 
GDNF - glial-derived neutotrophic factor 
GFAP - glial fibrillary acidic protein 
GLAST - L-glutamate/L-aspartate transporter 
GLT - glutamate transporter 
GTPase - guanosine triphosphatase 
HSP - heat shock protein 
IL- interleukin 
LPS - lipopolysacharide 
LTP - long-term potentiation 
MAPK - mitogen activated  protein kinase 
MD - co-myeloid differentiation 
mRNA - messenger ribonucleic acid 
MS-153 - (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline 
NAcc - nucleus accumbens 




NMDA - N-Methyl-D-aspartate 
NO - nitric oxid 
PDE - phosphodiesterase 
PAK - protein kinase A 
PNS - peripheral nervous system 
PPF - propentophylin 






























This review is focused on drugs of the group of opioids but, to a lesser extent, some attention 
is devoted also to amphetamine-type stimulants and cocaine and their effects on neuroglia. 
Opioids, mainly morphine, have been used for relieving pain for a long time. Their effects 
have been known since an ancient period. Except of their medical effects, opioids and their 
semi-synthetically/synthetically created chemical analogues can be unfortunately abused as 
psychoactive substances. Heroin is one of the most abused drugs of this type. According to 
WHO data, 230 million people used drugs at least once in 2010. There are about 27 million 
drug users what is 0.6 percent of adult population (UNODC, 2012). Heroin, cocaine and other 
drugs kill about 0.2 million people each year. Global opium production is amounted to 7000 
tons in 2011. Opioids continue to be a dominant drug type in Asia, Europe, North America 
and Oceania according to treatment demand. Amphetamine-type stimulants are dominant in 
Asia. The main problems related to use of drugs are tolerance, withdrawal and hyperalgesia. 
The fast development of science and technology allows to research in great detail 
molecular structures on the level of different proteins, receptors or DNA. Thanks to this, we 
have an opportunity to examine the effect different substances on organisms on the molecular 
level. Hughes et al. (1975) was one of the first, who isolated endogenous compounds binding 
to opioid receptors. Some organisms may produce endogenous opioids as a result of pain, 
reward or addiction. It is known that endogenous opioids affect the function of opioid 
receptors, which are highly abundant especially in the central nervous system. These receptors 
do not recognize only the opioids produced by own body but also react with appropriate 
substances from the outside. Opioid receptors have been found not only in the plasma 
membrane of neurons, but they are distributed also in glia.  
There numerous studies dealing with the effects of drugs on neurons. A few years ago 
scientists started to focus on glia cells, too. It was found that glia cells are not only supportive 
cells in the CNS and PNS but also play a role in communication between neurons, modulation 
of neurotransmission and production of factors such as cytokines and chemokines.  
There is still an open question about the role and possible participation of glia in the 







5. Basic information on addictive drugs  
5.1 Opioids 
Morphine, a typical representative of opioids, is an opioid analgesic drug and the main 
psychoactive chemical of opium. Opium is dried latex which is obtained from Papaver 
somniferum. From poppy seed it is isolated by Sertürner' method. A wide range of semi-
synthetic alkaloids created by simple chemical manipulations is very useful for medicine. 
Opioids can be divided into four groups, according to Drug Reinforcement Agency (Trescot 
et al., 2008):  
1) Phenantrenes are prototypical opioids. 6-hydroxyl group in the structure of these 
molecules may corfer a higher incidence of nausea and hallucinations. Opioids contained 
into this group are as follows: morphine, codeine, hydromorphone, levopranol, 
oxycodone, hydrocodone, oxymorphone, buprenorphine, nalbuphine and butorphanol. 
2) Benozonorphans with one member of this class: pentazocine. It is agonist/antagonist with 
a high incidence of dysphoria. 
3) Phenylpiperidines: a member of this group fentanyl has the highest affinity for the mu-
opioid receptor. Opioids in this group are fentanyl, affentanil, sufentanil, and meperidine. 
4) Diphenylheptanes: propoxyphene and methadone. 
Tramadol does not belong to any above mentioned groups of opioids. It is an atypical opioid, 
a 4-phenyl-piperidine analogue of codeine, with partial mu agonist activity in CNS. These 
effects are related to GABA, catecholamine and serotonergic activity in addiction. 
 
5.2 Amphetamine-type stimulants 
Methamphetamine and amphetamine are synthetic substances which do not occur in nature. 
Methamphetamine is amphetamine with one additional methyl group on the chain. 
Amphetamine-type stimulants (ATS) are structurally similar to noradrenaline and dopamine 
and are able to inhibit dopamine metabolism and its reuptake and increase the release 
noradrenaline and serotonin (Berridge et al., 2002; Kuczenski et al., 1995). The 
monoaminergic system increases after a dose of amphetamine. ATS cause enhancement of 
dopamine release from nerve terminals (Kogeles et al., 1999; Silvia et al.,1997).  
 
5.3 Cocaine 
Cocaine is an alkaloid from Erythroxylon coca and it is the only naturally existing local 




1997; Volkow et al., 2000). According to Rasmussen et al., 2001; Ritz et al., 1990). Cocaine 
can also block reuptake of noradrenaline and serotonin and may increase noradrenaline 
release (Tuncel et al., 2002). 
 
6. Basic concepts of drug addiction 
Tolerance, sensitization and dependence are associated with chronic drug addiction. Drugs of 
abuse target neutral processes which are involved in reward-based learning (Hyman et al., 
2006; Kalivas et al., 2008; Milton et al., 2010). Brain circuitry is the network of 
interconnected neurone throuhg which the electrical and chemical signals travel. Drugs of 
abuse afflict neurons interconnected in brain structures involved in reward-base learning. 
Nucleus accumbens, a region in the basal forebrain rostral to the preoptic area of the 
hypothalamus, is one of the most important structures implicated in drug addiction which play 
a role in psychological reward associated with addiction: learning, liking and wanting 
(Berridge et al., 2009). The NAcc and the olfactory tubercle form the ventral striatum, the part 
of basal ganglia. Dopamine activity in the NAcc does not habituate to repeat drug exposure by 
reduction of dopamine activity as it does after encounter with natural rewards (Wise et al., 
1995; Hemby et al., 1997). According to Cadoni et al. (1999 and 2000) repeated drug 
exposure induces sensitization of dopaminergic transmission in the NAcc core. Chronic drug-
induced dopamine stimulation may patologically strengthen the learning of stimuli related to 
drug availability via Pavlovian conditioning and the core with senzitized to dopamine 
transmission will start behavioral activity to obtain drug reward. Dopamine stimulation is 
connected to euphoric temper and  satisfaction.    
 
6.1. Tolerance, hyperalgesia and withdrawal 
6.1.1 Tolerance to opioid analgesia 
Opioid tolerance arises from repeated exposure to opioids and it is the manifestation of 
decreasing therapeutic effect and requirement for higher dose to maintain the same effect. 
According to Toda et al. (2009) three are specific signalling pathways involved in this process 
and according to Christie (2008) pharmacodynamic tolerance includes the following changes 
at different levels: 
1) mu-opioid receptor: loss of intracellular signalling pathway capacity due to  
 decreased expression and/or reduced coupling efficacy 




3) at the system: adaptation to a network not related to mu-opioid receptor such as ORL1, 
 choleocystokinin, NK1 signalling. 
 
  
6.1.2 Hyperalgesia and allodynia  
Allodynia  is a pain caused by stimuli (temperature, physical stimuli) which normally do not 
provoke pain. By contrast, hyperalgesia is a massive exaggerated reaction on stimuli which 
are normally painful.  
Opioid-induced hyperalgesia and opioid withdrawal-induced hyperalgesia have been 
shown to increase pain sensitivity. The studies of Dourish et al. (1988), Xu et al. (1992) and 
Vanderah et al. (2000,2001) claim that opioid-induced hyperalgesia is a result of increasing 
amounts of excitatory neurotransmitters such as choleocystokinin, which activates production 
of spinal dynorphins. Dynorphins are class of the opioid peptides from the precursor protein 
prodynorphin. Proprotein convertase 2 cleaves prodynorphine, which causes release of 
peptides such as: dynorphin A, dynorphin B, alpha/beta-neo-endomorphines. These peptides 
are involved in pain response (Han et al., 1984).  
 
6.1.3. Withdrawal 
The studies of  Wang et al. (1997) and Volkow et al. (2007), and Martinez et al. (2004, 2005) 
have shown that withdrawal is associated with hypofunction in dopamine pathways, which is 
underlain by reduction of D2 receptor expression and dopamine release. Diminution of the 




The neurocircuitry (Fig. 1 and 2) forms the neuroplasticity associated with the development of 
drug abuse. Five circuits are involed in addiction: (1) the mesolimbic dopamine system, (2) 
the ventral striatum, (3) the ventral striatum/dorsal striatum/thalamus circuits, (4) the 










Fig. 1. Neurocircuitry. Adopted from Koob et al. (2008). 
 
 
Glutamate is the main excitatory transmitter in the brain, which is involved in different 
brain function such as cognition, memory and learning. There are four types of glutamate 
receptors: NMDA, AMPA, delta and kainate receptors (summarized in Traynelis et al., 2010). 
All these receptors are nonselective cation channels, allowing the passage of Na+ and K+ and 
in come cases Ca2+ ions through the plasma membrane. Long-term potentiation (LTP) is a 
long-lasting increasing in signal transmission between two neurons which are stimulated at 
the same time (Cooke et al., 2006). It is one of the substantial mechanisms of synaptic 
plasticity whereby chemical synapses are able to change their strength. LTP is one of the 
major cellular mechanisms that are involved in learning and memory. It has been observed 
that  in vivo exposure to morphine and nicotine induced LTP to AMPA-mediated 
neurotransmission in dopaminergic neurons (Saal et al., 2003). Not only morphine and 
nicotine but also amphetamine and cocaine  can induce this effect (Sun et al., 2005). 




(Chen et al., 2008). According to the study of Pierce et al. (1996) chronic cocaine exposure of 
rats elevated glutamate neurotransmission and these animals showed behavioral sensitization. 
Glutamatergic activity in NAcc slices strengthens LTP (Yao et al., 2004). Studies of 
Bondreau et al. (2005) and Conrad et al. (2008) demonstrated that three weeks of cocaine 
exposure increase the ratio of glutamate-1 receptors (GluR1) and on neurons which have low 
number of GluR2 was observed a slow redistribution of AMPA receptors. According to study 
of Chao et al. (2002), the expression of AMPA receptors depends on activation of dopamine 
D1 receptors and protein kinase A signalling. In study of Sutton et al. (2003) overexpression 
of GluR1 in the NAc relieved extinction of cocaine-seeking answers and increased threshold 
of reward. These changes resulted in (1) decreased reward and (2) lack of motivation 
(Todtenkopf et al., 2006). According to Nelson et al. (2009) the increase of AMPA expression 
does not occur in the amphetamine-sensitized rat. These observations led to a hypothesis of 
different functional effects of glutamate projections (Nelson et al., 2009). 
Chronic cocaine administration inhibits basal release of glutamate but sensitizes 
synaptic glutamate release during restitution of obliterate of extinguished drug-seeking in rats 
(Kalivas et al, 2008; McFarland et al., 2003). Dysregulation of the cystine-glutamate 
exchange is another molecular target for regulation of the plasticity. According to study of 
Baker et al. (2003), chronic exposure to cocaine slows down cystine-glutamate exchange, 
leading to reduced basal and increased drug-induced glutamate in the NAcc. Cystin-glutamate 
exchanger controls the extracellular glutamate concentration. According to study of Kalivas 
(2004), lower basal levels of glutamate combined with elevation of synaptic glutamate from 
the prefrontal cortex afferens to the NAcc are the result of engaging in drug-seeking. 
Long-lasting synaptic effects are characterized by (1) a decrease of glutamatergic 
neurotransmission during chronic exposure to the drug and (2) a persistent increase in the 
effectiveness of glutamatergic synaptic neurotransmission during recovery following 
withdrawal. These alternations promote excitation of the cells and are the base of drug-related 


























Fig. 2. Outline of neurocircitry of reward (natural and drug) on the level of receptors and their 
releasing factors. For more information see text above. Adopted from Philibin et al. (2011). 
 
 
6.3. Molecular pathways of neuroplasticity 
Molecular pathways involbed in natural and drug reward are summarised in Fig. 2 and 3. 
According to study of Edwards et al. (2007), chronic administration of opiates and cocaine 
leads to activation of cAMP-element binding protein (CREB) in the NAcc and CeA. CREB is 
a cellular transcription factor which is phosphorylated by protein kinase A (PKA). PKA 
regulates growth factors. PKA is setting in a point of convergence for some intracellular 
messenger pathway, which regulates gene expression. In study of Olson (2005) activation of 
CREB in the NAcc was connected to motivational symptoms of psychostimulant withdrawal. 
This process could be caused by induction of the dynorphin, which is opioid peptide that 
binds to kappa-opioid receptors and may be involved in the mechanism of depence and 
tolerance. Recurring CREB activation can support dynorphin expression in the NAcc which in 
turn inhibits dopaminergic activity. This modulation of dopaminergic signaling may cause 




Different transcription factors can be activated by CREB and other intracellular 
messengers. This activation leads to long-term changes in protein expression and as a result, 
neuronal function. According to study of Olson (2005), acute administration of drugs of abuse 
causes activation of the elements of the Fos protein family such as c-fos, FosB, Fra-1 and Fra-
2 in the NAcc. In a longer period of time (days) also other transcription factors are activated, 
such as deltaFosB, which are a highly stable form of FosB. Activated dFosB may increase 



















Fig. 3. Outline the molecular pathway of natural and drug reward. See text above. Adopted 
from Philibin et al. (2011). 
 
Summary of changes in gene expression after long-term administration of drugs: 
1) signal transduction in kappa opioid receptors (Fan et al., 2002; Kaewsuk et al.,  
 2001; Przewlocka et al; 1994) 
2) calcium binding proteins (Tirumalai and Howels, 1994) 





7.1 Opioid receptors 
There is four types of opioid receptors: mu, delta, kappa and ORL1. ORL1 is genetically 
closely related to others. Activated opioid receptors tranduce signals through their cognate 
heterotrimeric G-proteins (Fig. 4.). All opioid receptors are 7-transmembrane spanning 
proteins that are connected to the inhibitory G-proteins. According to Childers et al. (1978), 
Galpha and Gbetagama subunits of G-proteins dissociate from one another after stimulation 
and act on intracellular effector pathways. It was found that GTPase activity of the G-protein 
alpha subunit is stimulated by endogenous opioid peptides or opioid agonists (Barchfeld et al., 
1984). Stimulation of opioid receptors also inhibits cAMP production (Minneman et al., 
1976). There is the inhibitory function on cAMP signalling which is Galpha dependent (Hsia 
et al., 1984; Taussig et al., 1993). Opioid receptors are also able to modulate calcium and 
potassium ion channels. In study of Rusin et al. (1997), opioid agonists caused a decrease in 
Ca2+ because they reduced P/Q-type, N-type and L-type currents. This effect was a result of 
binding of the dissociated Gbetagamma subunits directly to these ion channels and reduction 




















According to Sibinga and Goldstein (1988), interaction of opioids with opioids receptors can 
be characterized as follows: 
1) opioid ligand needs an intact NH2 terminus of the receptor 
2) in the presence of GTP or increased concentration of sodium ion, opioid agonist 
binding is reduced; on the other hand, there is a minimal effect on an antagonist 
activity 
3) binding to an opioid receptor is often of high afinity and stereoselective 
4) binding is blocked by opioid antagonist such as naloxone 
5) novel sites binding has similar afinity with previous opioids receptors 
6) responses are pertussis-toxin sensitive involving receptor coupling to a G-protein 
 
7.2 Opioid receptors in glial cells 
Distribution of opioid receptors in astrocytes was determined in the following studies:  
1) mu-opioid receptor (Dobrenis et al., 1995; Hauser et al., 1996; Ruzicka et al.,  
 1996; Festa et al., 2002) 
2) kappa-opioid receptor (Bunn et al., 1985;  Maderspach et al., 1995) 
3) delta-opioid receptor (Thorlin et al., 1998). 
 
There is a lower level of mu-receptor mRNA, as compares with kappa- and delta-
opioid receptors, in cortical, striatal, cerebellar, hippocampal and hypothalamic astrocytes 
(Ruzicka et al., 1995). The level of mRNA expression of opioid receptors in different 
astrocyte cultures is in the following order: cortex > hypothalamus > cerebellum + 
hippocampus > striatum (Ruzicka et al., 1995). 
Mu-opioid receptor occurs in the spinal cord (Cheng et al., 1997), nucleus tractus 
solitarius (Glass et al., 2002), dentate gyrus (Drake et al., 2002), caudate putamen (Rodriguez 
et al., 2001) and nucleus accumbens. In the posterior pituitary was observed the greatest 
expression of kappa-opioid receptor (Bunn et al., 1985; Burnard et al., 1991). Microglia also 
express opioid receptors according to study of Horvath et al. (2010). Oligodendrocytes also 
express mu-opioid receptor (Knapp and Hauser, 1996; Knapp et al., 1998; Tryoen-Toth et al., 
2000) and kappa-opioid receptor (Tryoen-Toth et al., 1998). According to study of Knapp et 







TLR4 is a receptor which detects lipopolysacharide (LPS) from Gram-negative bacteria and 
its role is the activation of the innate immune system. Interestingly, morphine can bind 
directly to TLR4 and its effect is associated with exaggerated response mediated via TLR4 
and microglial activation after this drug administration in adolescence. The increased 
responsiveness could increase risk of drug-induced reinstatement in adulthood (Schwarz et al., 
2013). These effects of morphine on microglia were studied in the region of the NAcc. 
Opioid-induced glia activation increases tolerance, dependence, reward and breathing 
decrease. Intriguingly, these effects are apparently not the result of activation of opioid 
receptors, but TLR4, which is also at the same time the main glial receptor which participates 
in neuropathic pain (Watkins et al., 2009). 
 
7.3.1 TL4 Glial activator receptor 
TLR4 is mainly expressed by microglia, however, it can be found also in astrocytes, 
especially under neuroinflammatory conditions (Hutchinson et al., 2008). This receptor 
appears to be a major glial activator at the beginning of and during neuropathic pain. 
Although the TLR2 and TLR3 receptors are involved in neuropathic pain, most studies have 
been done just for the TLR4 receptor. There are several studies dealing with TLR2 (Mallard 
et al., 2009; Hong et al., 2010) and TLR3 (Obata et al., 2008).  
 
7.3.2 TLR4 signalling 
TLR4 signalling is active in a number of cellular cascades. It has been reported that LPS, 
which is agonist of TLR4 receptor, after interaction with LPS-binding protein is transferred to 
CD14 co-receptor on the cell membrane (Laird, 2009). This leads to intracellular activation of 
acid sphingomyelinase, which generates ceramide. Subsequently, lipid rafts are formed 
containing MD2, which is co-myeloid differentiation factor receptor, interacting with TLR4, 
HSP 70, 90 and others. CD14 brings LPS to the vicinity of MD2 and interaction of these 
proteins results in heterodimerization and subsequently to homodimerization of MD2-TLR4 
(Fig. 5.). The following intracellular signalling steps occur through at least three parallel 
paths. The first two, cell movement and cell survival/apoptosis are mediated via the 
PI3K/Akt. The third one, which leads to production of pro-inflammatory factors, is mediated 













Neuroglia are cells in the central and peripheral nervous system which play a crucial role in 
maintenance and protection of neurons. These cells participate in nutrient supply, defensive 




cells in the central and peripheral nervous system, but also play a crucial role in 
communication, modification of neuron’s answer and releasing factors such as cytokines and 
chemokines. 
Glia cells are divided according to their morphological and functional characteristics. 
According to morphological differences these cells are divided into two groups: microglia and 
macroglia (astrocytes and oligodendrocytes in this study).  
Studies dealing with the effects of drugs on glial cells were conducted mainly on 
astrocytes, microglia and oligodendrocytes. There are several in vitro studies that revealed a 
direct action of opioids on glia (Hutchinson et al., 2008; Narita et al., 2006; Horvath et al., 
2009; Takayama et al., 2005). According to works of Hutchinson et al. (2008) and Tawfik et 
al. (2005), opioids activate glial cells and this activation leads to release of pro-inflammatory 
products, including cytokines. Hauser (1996) and Merrill and Benveniste (1996) reported that 
a lot of neuronal signals such as ATP, NO, substation P, excitatory amino acids or 
proinflammatory cytokines can also stimulate glia.  
 Under in vivo conditions, activation of glia by drugs could happen via microglial or 
astrocytic activation markers, which are induced by morphine (Cui et al., 2006, Hutchinson et 
al., 2009). Activation of glia by drugs could block the pro-inflammatory cytokines which 
increase the morphine analgesia (Hutchinson et al., 2008; Shavit et al., 2005). According to 
study of Cui et al. (2006), selective activation of microglial p38 MAPK is induced by opioids 
and inhibition of p38 MAPK attenuates tolerance to morphine algesia.  
 
8.1 Astrocytes 
These cells were introduced by Michael von Lenhossek in 1891 (Parpura et al., 2012). 
Besides others, the role of astrocytes is delivery of nutrients and neurotransmitter precursors 
and regulation of cerebral blood flow. According to Smith (2010), astrocyte may have about 
30,000 connections with adjacent cells. These connections provide integrating and 
modulatory capability. Astrocytes can regulate nervous transmission in the following ways: 
1) by releasing of neurotransmitters (Fellin and Carmignoto, 2004) 
2) by neurotrophic factors (Brenneman et al., 1997) 
3) by cytokines and chemokines (Dong and Benveniste, 2001) 
4) by formation of extracellular matrix (Brightman, 2002).  
Astrocytes are distributed in all parts of the CNS and they have a lot of different functions, 




synapse (Araque et al., 1999). The tripartite synapse (Fig. 6) is a concept of existence of 
bidirectional interactions between astrocytes and neurons, whereby astrocytes may modulate 
communication between presynaptic and postsynaptic neuron. This modulation reflects active 
participation of astrocytes in a synaptic function. 
  
 
Fig. 6. Tripartite synapse: the transmission of information between a presynaptic and 
postsynaptic neuron and astrocyte. Adopted from Araque et al. (1999).  
 
In addiction the role of astrocytes is in maintenance of glutamate homeostasis, which has an 
important role in the synaptic activity, and high doses of extracellular glutamate may cause 
influx of calcium ions into the neurons and result in uncontrolled signaling and neurotoxicity. 
There are two main types of glutamate transporters: EAAT1 (rat homolog glutamate/aspartate 
transporter GLAST) and EAAT2 (rat homolog glutamate transporter -1, GLT-1) (Hertz et al., 
2004). These transporters are primarily expressed in astrocytes but they are also in other 
neuroglia in a limited extent. According to studies of Hyman et al. (2005) and Kalivas (2004), 
the glutamatergic system is involved in the process of learning which leads to behavior during 
addiction. Glutamate transport activator MS-153, when applied along with morphine, 
methamphetamine, or also cocaine, could significantly reduce place preference without 




reduce the development of morphine tolerance and physical addiction when applied along 
with morphine (Nakagawa et al., 2001). 
To determine the role of astrocytes, astrocyte conditioned medium (ACM) was used in 
experiments of Narita et al. (2006). ACM is used to support growth of neurons and 
endothelial cells and in this study it was applied for investigation how astrocyte-related 
soluble factors are involved in the development of rewarding effects induced by drugs of 
abuse. Application of ACM into the NAcc of a mouse after administration of 
methamphetamine or morphine in a dose which causes addiction increased rewarding effects 
of these drugs by the way of activation of the Janus kinase signal transducers and activators of 
transcription (Jak/STAT) pathway, which modulates astrogliosis and astrogliogenesis.  
 
8.1.1. GFAP 
GFAP protein is the main protein of intermediate filaments of glial cells in differential fibrous 
and protoplasmatic astrocytes in the CNS. GFAP is part of cytoskeleton and is important for 
keeping the cell shape. Astrocytes in drug addicts show elongated fiber structures which 
contain a significant amount of GFAP in comparison with control samples. The changes are 
prominent in hippocampal astrocytes (Weber et al., 2013). Interestingly, brain injury and 
neurotoxicity is also accompanied by increased levels of GFAP (Hill et al., 1996). A long-
term therapy with morphine increases the expression of GFAP and enlargement of astrocytes 
in the ventral segmental area, frontal cortex, NAcc, locus coeruleus and nucleus of the solitary 
tracts in rats (Marie-Claire, et al., 2004; Beitner-Johnson et al., 1993; Song et al., 2001; 
Garrido et al, 2005; Alonso et al., 2007). Methamphetamine reduces dopaminergic terminals 
without loss of neurons (Ricaurte et al., 1984), but induces astrogliosis with increasing of 
GFAP in the frontal cortex, striatum and hipocampus (Pubill et al., 2003). 
It was observed that astrocytes inactivation by the gliotoxin fluorocitrate inhibits 
morphine-induced increasing of GFAP, toleration and morphine analgesia (Song et al., 2001). 
MDMA (Ecstasy) is an exception in comparison to other stimulants, because it does not 
increase GFAP expression or activation of microglia, although it causes reduction of 
dopaminergic and serotonergic terminals (Pubill et al., 2003). 
Narita et al. (2006) reported that in vitro treatment of a mouse neural/glial cells in 
culture with methamphetamine (10 uM) or morphine (10 uM) during the period of three days 
caused activation of astrocytes and at the same time increased the level of GFAP and did not 




same group (Narita et al., 2005). On the other hand, morphine (10 uM) but not 
methamphetamine (10 uM) induced activation of cortical astrocytes.  
Propentophylline is a xantine derivate known for its neuroprotective effects and it has 
been shown to modulate a glial activity under pathological conditions when astrocytes are 
activated by methamphetamine and morphine (Sweitzer et al., 2001; Rhagavendra et al., 
2004). Amphetamine may cause reduction in striatal neuroglia and gliogenesis in the 
subventricular zone and the somatosensory cortex in vivo. Liu et al. (2013) reported changes 




The neurotrophic activity of astrocytes can participate in the effects of cocaine in the ventral 
tegmental area. Glia-derived neurotrophic factor (GDNF) is mainly in astrocytes, but it is 
produced in microglia, too (Appel et al., 1997; Chang et al., 2006). GDNF supports survival 
and differentiation of dopaminergic neurons and protects these cells from methamphetamine- 
induced neurotoxicity in mice (Cass, 1996). As observed in study of Pierce et al. (2001), after 
administration of GDNF into the VTA a significant reduction occured in the increase of a key 
protein, neurotrophin, induced by exposure to cocaine. 
 
8.1.3. BDNF 
BDNF produced mostly by astrocytes plays a role as a factor of survival for some neurons and 
it participates in synaptic plasticity in the cortex and other subcortical. The BDNF signaling 
pathway, which starts from non-noradrenergic sources such astrocytes, is essential for opioid 
induced adaptation of the noradrenergic system (Akbarian et al., 2002). This factor can also 
be involved in response to withdrawal symptoms (Akbarian et al., 2001). The BDNF/TrkB 




Astrocytes produce not only BDNF, but also bFGF, which plays a role in the development of 
sensitivity to amphetamines (Yamada et al., 2004). According to the study of Fumagalli et al. 
(2006), one dose of cocaine transiently increased the level of bFGF in the striatum and 







Microglia was discovered by Pio del Rio-Hortega in 1932 (summarized in Rezaie et al., 
2002). These cells originate from  monocytes and their role is phagocytosis in the CNS. 
Microglia respond to damage or stress situations in the CNS. Activation of microglia includes 
always proliferation of these cells or increase of expression of immunomolecules or changes 
of their function such as release of cytotoxic or/and inflammatory mediators. 
Microglia, similarly to the other cells in the immune system, express opioid receptors 
(Bidlack, 2000; Chao et al., 1997). Hu et al. (2002) have shown that overstimulation of these 
receptors leads to apoptosis. Stimulation by morphine can stimulate phagocytosis (Peterson et 
al., 1995; Lipovsky et al., 1998) and decrease microglial chemotaxis via complement protein 
5a (Chao et al., 1997) and CCL5 (Hu et al., 2000). On the other hand, study of Shanks et al. 
(2012) revealed that methamphetamine but not amphetamine can inhibit phagocytosis. 
According to De Leo (2006) microglia can modulate neuron response similarly to astrocytes. 





















Below is summarized experimental evidence concerning microglia activation mechanisms 
after nerve injury, surgical procedures and chronic opioid exposure:  
1) Phosphorylation of p38 through activation of P2X4 receptor and increased synthesis 
and release of the neurotrophin BDNF, which, among others, might increase 
neuropathic pain through the inhibition of synaptic transmission in the spinal cord 
(Wu et al., 2006). 
2) At the same time, this phosphorylation increases the synthesis of pro-inflammatory 
 cytokine IL-1b, IL-6, TNF-alpha and the transcription factor NF-kB (Haydon et al., 
 2009),  LPS, which is a potential activator of microglia and TLR4  ligand,  which  
 indicates the release of other glia. 
3) Increased IL-1b, IL-6 and TNF-a indicate the hyperactivity of neurons in the dorsal 
root of the rear corners. This condition leads to hypersensitivity (Hutchinson et al., 
2007; Noman  et al., 2009). 
4) Intratecal administration of IL-1b, IL-6, TNF-a induces potent hyperalgesia and 
allodynia. CREB activates the same factors which are critical in transcription of 
pronociceptive genes such as neurokinin-1 and Cox-2 (Lewis et al., 2009). 
In the study of Viviani et al. (2003), IL-1B increased NMDA conductance in neurons 
also in the spinal cord dorsal horn. According to study of Beattie et al. (2002), TNF-alpha 
significantly enhances membrane neuronal AMPA receptors and conductance. TNF-alpha 
also increases neuroexcitability in response to glutamate (Emch et al., 2001). 
 
8.3. Oligodendrocytes 
The role of oligodendrocytes is in maintenance and isolation of neuron axons in the CNS. The 
same role with some morphological differences is played by Swan’s cells in the PNS. One 
oligodendrocyte may roll with myelin approximately 50 axons. Oligodendrocytes are not as 
well characterized as astrocytes or microglia cells as far as their role in drug addiction 
concerned. Bannon et al. (2005) and Albertson et al. (2004) have found using microarrays that 
the expression of mRNAs of many proteins is greatly reduced in patients addicted to cocaine. 
These proteins are involved in the process of myelination in the NAcc, which has been 
reduced to oligodendrocytes immunoreactive for myelin basic protein. At the moment there 
are no studies where the correlation between the change in behavior among drug addicts and 




Oligodendrocytes, like other glial cells, are capable of producing neurotrophic factors in 
response to the surrounding neurons (Du et al., 2002). 
 
9. Minocycline, fluorocitrat and ibudiblast (AV411)  
These substances are in the center of interest of many scientists (Meller et al., 1994; Milligan 
et al., 2000 and 2003; Ragavendra et al., 2003;  Ledeboer et al., 2005) because of their effects 
on neuroglia in pain control. Glial activation inhibitors such as fluorocitrat, minocycline and 
possibly ibudilast (AV411) increase the morphine analgesia (Hutchinson et al., 2008, 
Hutchinson et al., 2009; Cui et al., 2008). They can be important in prevention of hyperalgesia 
or relieving of symptoms associated with long-term use of drugs. 
Fluorocitrate, a metabolite of fluoroacetate, according to study of Hassel et al. (1992) 
disrupts the Krebs cycle via inhibiting aconitase. Berg-Johnsen et al. (1993) observed that this 
compound causes reduction in the glial tricarboxylic acid cycle and accordingly in the level of 
glutamine, the main precursor of glutamate. 
Minocycline, a  broad-spectrum tetracyclic antibiotic,  inhibits activation of microglia 
but, on the other hand, it does not exert any direct effect on neurons or astrocytes (Ledeboer et 
al., 2005) and stops locomotor activity induced by cocaine or methamphetamine in mice 
(Chen et al., 2009; Fujita et al., 2012).  
Ibudilast (AV411), 3-isobutyryl-2-isopropylpyrazolo-[1,5-a]pyridine, was found  to 
inhibit phosphodiesterase (PDE) and pro-inflammatory activity. In parallel, administration of 
AV411 blocked the response to methamphetamine exposure in rats (Snider et al., 2013; 
Beardsley et al., 2010). AV411 may decrease opioid dependence and withdrawal signs 
(Hutchinson et al., 2009; Ledeboer et al., 2007) and also attenuate morphine-induced release 




Neuroglia are not only supportive cells in the CNS and PNS but also play a lot of other 
important roles. The substances such as drugs of abuse can activate these cells in a specific 
way. The studies dealing with the effects of drugs on glia have been mainly performed on on 
astrocytes, microglia and oligodendrocytes. 
The best reviewed glia are astrocytes which after their activation are able to produce 
cytokines and chemokines (Achour and Pascual, 2010). According to Araque (1999) there is a 




an astrocyte and presynaptic and postsynaptic neuron. As a result of this modulation there is 
an active participation of astrocyte in a synaptic function. In the study of Hertz et al., 2004, 
the role of astrocytes in addiction is the keeping of glutamate homeostasis, which has an 
important role in the synaptic activity. There is a direct evidence that among drug addicts the 
level of GFAP is higher (Weber et al., 2013; Marie-Claire et al., 2004; Beitner-Johnson et al., 
1993; Song et al., 2001; Garrido et al., 2005; Alonso et al., 2007), also GDNF (Appel et al., 
1997; Lee et al., 2006), BDNF (Akbarian et al., 2002, 2001), bFGF (Yamada et al., 2004; 
Fungamalli et al., 2006) in comparison with control samples. 
Microglia, main cells of the immune system in the brain, are important for their role in 
phagocytosis (Peterson et al., 1995; Lipovsky et al., 1998) but they are involved in 
chemotaxis, too (Chao et al., 1997; Hu et al., 2000). According to De Leo (2006), microglia 
provide a modulation of neuron response similarly to astrocytes, and they are part of a 
tetrapartite synapse.  
It has been demonstrated that glial cells after activation by opioids increase tolerance, 
dependence, reward and depress breathing. These effects depend mainly on TLR4 and less on 
opioid receptors (Watkins et al., 2009). TLR4 is the main glial receptor which participates in 
neutropathic pain.  
Fewer studies have been devoted to oligodendrocytes. However, it has been found that 
many proteins expressed in these cells involved in the process of myelination are reduced in 
patients addicted to cocaine (Bannon et al., 2005; Albertson et al., (2004).  
Promise for the future lies in the prevention of allodynia and hyperalgesia (Meller et 
al., 1997; Milligan et al., 2000 and 2003; Rhagavendra et al, 2003; Ledeboer et al., 2005) 
therefore substances like minocycline, which inhibits activation of microglia (Ledeboere et 
al., 2005), fluorocitrate, which inhibits activation of astrocytes (Hassel et al., 1992; Borg-
Johnsen et al., 1993) or ibudilast (AV411), which inhibit phosphodiesterase (PDE) and pro-
inflammatory activity. (Snider et al., 2013; Beardsley et al., 2010). However, more research 
focused on these substances is needed.  
There is a number of studies dealing with consequences of drug administration in 
neurons but there are only few studies about the role of glia in the mechanism of tolerance, 
withdrawal and hyperalgesia. It is necessary to pay more attention to delineation of 
communication between glia and neurons, glial receptors, modulation of synaptic 
transmission, influence of opioid-induced releasing factors, and others.  




1) studies of oligodendrocytes, Swan cells and other types of glia and their 
 modification after drug administration 
2) investigation of the consequences of increased levels of GFAP, GDNF, BDNF, bFGF 
3) possible use of minocycline, fluorocitrate and ibudilast (AV411) in a prevention of 
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